Diagnostic accuracy for alcoholic liver disease with controlled Attenuation Parameter (CAP) measured by transient elastography for the non-invasive assessment of liver steatosis

Masahiro Kikuchi, Rumiko Umeda, Kota Tsuruya, Hirokazu Shiozawa, Masashi Matsushima, Keiichiro Abe, Miho Kikuchi, Masahiko Takahashi, Yoshiyuki Yamagishi, Hiroyasu Nishizaki, Yoshinori Horie, Takanori Kanai

Research output: Contribution to journalArticle

Abstract

Along with the development of interferon and therapeutic medication, the incidence of viral hepatitis constituting the largest part of liver disease decreased, and the main target in the field of liver disease is now shifting from viral hepatitis to alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) as metabolic liver disease. Although these diseases tend.to. be gathered as non-viral liver disease because the similar specific liver tissue, the natural history and etiology are considerably different between them. We need to distinguish both of them to do appropriate treatment intervention. Questioning of amount of drinking is needed, but we experience some difficult cases to understand drinking history because of a too little declaration of amount of drinking. A new ultrasonic image analyses using propagation speed in the organization of the pulse vibration wave was developed as Fibroscan by Echosens company in recent years. Fibroscan is a non-invasive test to quantify liver fibrosis as Liver Stiffness Measurement (LSM). It also detects and quantifies steatosis simultaneously using the Controlled Attenuation Parameter (CAP). CAP is a measurement of the ultrasound attenuation. We measured liver steatosis of patients using Fibroscan, and other blood tests. 63 cases of ALD, 177 cases of NAFLD, 57 cases of Virus and 271 cases of Normal were enrolled. CAP value were significantly lower in the ALD group compared with NAFLD group. (P <0.0053, ALD 268 dB/m : NAFLD 290 dB/m) We elucidate the diagnostic accuracy of CAP using Fibroscan for ALD patients, comparing the results of them to those of virus patients and NAFLD patients.

Original languageEnglish
Pages (from-to)235-247
Number of pages13
JournalNihon Arukōru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence
Volume50
Issue number5
Publication statusPublished - 2015 Oct 1

Fingerprint

Elasticity Imaging Techniques
Alcoholic Liver Diseases
Fatty Liver
Liver Diseases
Drinking
Hepatitis
Viruses
Liver
Metabolic Diseases
Hematologic Tests
Vibration
Natural History
Ultrasonics
Liver Cirrhosis
Interferons
Non-alcoholic Fatty Liver Disease
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Diagnostic accuracy for alcoholic liver disease with controlled Attenuation Parameter (CAP) measured by transient elastography for the non-invasive assessment of liver steatosis. / Kikuchi, Masahiro; Umeda, Rumiko; Tsuruya, Kota; Shiozawa, Hirokazu; Matsushima, Masashi; Abe, Keiichiro; Kikuchi, Miho; Takahashi, Masahiko; Yamagishi, Yoshiyuki; Nishizaki, Hiroyasu; Horie, Yoshinori; Kanai, Takanori.

In: Nihon Arukōru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence, Vol. 50, No. 5, 01.10.2015, p. 235-247.

Research output: Contribution to journalArticle

Kikuchi, Masahiro ; Umeda, Rumiko ; Tsuruya, Kota ; Shiozawa, Hirokazu ; Matsushima, Masashi ; Abe, Keiichiro ; Kikuchi, Miho ; Takahashi, Masahiko ; Yamagishi, Yoshiyuki ; Nishizaki, Hiroyasu ; Horie, Yoshinori ; Kanai, Takanori. / Diagnostic accuracy for alcoholic liver disease with controlled Attenuation Parameter (CAP) measured by transient elastography for the non-invasive assessment of liver steatosis. In: Nihon Arukōru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence. 2015 ; Vol. 50, No. 5. pp. 235-247.
@article{b58f7e9cc84d47bd8fd96570debe0392,
title = "Diagnostic accuracy for alcoholic liver disease with controlled Attenuation Parameter (CAP) measured by transient elastography for the non-invasive assessment of liver steatosis",
abstract = "Along with the development of interferon and therapeutic medication, the incidence of viral hepatitis constituting the largest part of liver disease decreased, and the main target in the field of liver disease is now shifting from viral hepatitis to alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) as metabolic liver disease. Although these diseases tend.to. be gathered as non-viral liver disease because the similar specific liver tissue, the natural history and etiology are considerably different between them. We need to distinguish both of them to do appropriate treatment intervention. Questioning of amount of drinking is needed, but we experience some difficult cases to understand drinking history because of a too little declaration of amount of drinking. A new ultrasonic image analyses using propagation speed in the organization of the pulse vibration wave was developed as Fibroscan by Echosens company in recent years. Fibroscan is a non-invasive test to quantify liver fibrosis as Liver Stiffness Measurement (LSM). It also detects and quantifies steatosis simultaneously using the Controlled Attenuation Parameter (CAP). CAP is a measurement of the ultrasound attenuation. We measured liver steatosis of patients using Fibroscan, and other blood tests. 63 cases of ALD, 177 cases of NAFLD, 57 cases of Virus and 271 cases of Normal were enrolled. CAP value were significantly lower in the ALD group compared with NAFLD group. (P <0.0053, ALD 268 dB/m : NAFLD 290 dB/m) We elucidate the diagnostic accuracy of CAP using Fibroscan for ALD patients, comparing the results of them to those of virus patients and NAFLD patients.",
author = "Masahiro Kikuchi and Rumiko Umeda and Kota Tsuruya and Hirokazu Shiozawa and Masashi Matsushima and Keiichiro Abe and Miho Kikuchi and Masahiko Takahashi and Yoshiyuki Yamagishi and Hiroyasu Nishizaki and Yoshinori Horie and Takanori Kanai",
year = "2015",
month = "10",
day = "1",
language = "English",
volume = "50",
pages = "235--247",
journal = "Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence",
issn = "1341-8963",
publisher = "Nihon Arukoru Igakkai/Japenese Medical Society of Alcohol Studies",
number = "5",

}

TY - JOUR

T1 - Diagnostic accuracy for alcoholic liver disease with controlled Attenuation Parameter (CAP) measured by transient elastography for the non-invasive assessment of liver steatosis

AU - Kikuchi, Masahiro

AU - Umeda, Rumiko

AU - Tsuruya, Kota

AU - Shiozawa, Hirokazu

AU - Matsushima, Masashi

AU - Abe, Keiichiro

AU - Kikuchi, Miho

AU - Takahashi, Masahiko

AU - Yamagishi, Yoshiyuki

AU - Nishizaki, Hiroyasu

AU - Horie, Yoshinori

AU - Kanai, Takanori

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Along with the development of interferon and therapeutic medication, the incidence of viral hepatitis constituting the largest part of liver disease decreased, and the main target in the field of liver disease is now shifting from viral hepatitis to alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) as metabolic liver disease. Although these diseases tend.to. be gathered as non-viral liver disease because the similar specific liver tissue, the natural history and etiology are considerably different between them. We need to distinguish both of them to do appropriate treatment intervention. Questioning of amount of drinking is needed, but we experience some difficult cases to understand drinking history because of a too little declaration of amount of drinking. A new ultrasonic image analyses using propagation speed in the organization of the pulse vibration wave was developed as Fibroscan by Echosens company in recent years. Fibroscan is a non-invasive test to quantify liver fibrosis as Liver Stiffness Measurement (LSM). It also detects and quantifies steatosis simultaneously using the Controlled Attenuation Parameter (CAP). CAP is a measurement of the ultrasound attenuation. We measured liver steatosis of patients using Fibroscan, and other blood tests. 63 cases of ALD, 177 cases of NAFLD, 57 cases of Virus and 271 cases of Normal were enrolled. CAP value were significantly lower in the ALD group compared with NAFLD group. (P <0.0053, ALD 268 dB/m : NAFLD 290 dB/m) We elucidate the diagnostic accuracy of CAP using Fibroscan for ALD patients, comparing the results of them to those of virus patients and NAFLD patients.

AB - Along with the development of interferon and therapeutic medication, the incidence of viral hepatitis constituting the largest part of liver disease decreased, and the main target in the field of liver disease is now shifting from viral hepatitis to alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) as metabolic liver disease. Although these diseases tend.to. be gathered as non-viral liver disease because the similar specific liver tissue, the natural history and etiology are considerably different between them. We need to distinguish both of them to do appropriate treatment intervention. Questioning of amount of drinking is needed, but we experience some difficult cases to understand drinking history because of a too little declaration of amount of drinking. A new ultrasonic image analyses using propagation speed in the organization of the pulse vibration wave was developed as Fibroscan by Echosens company in recent years. Fibroscan is a non-invasive test to quantify liver fibrosis as Liver Stiffness Measurement (LSM). It also detects and quantifies steatosis simultaneously using the Controlled Attenuation Parameter (CAP). CAP is a measurement of the ultrasound attenuation. We measured liver steatosis of patients using Fibroscan, and other blood tests. 63 cases of ALD, 177 cases of NAFLD, 57 cases of Virus and 271 cases of Normal were enrolled. CAP value were significantly lower in the ALD group compared with NAFLD group. (P <0.0053, ALD 268 dB/m : NAFLD 290 dB/m) We elucidate the diagnostic accuracy of CAP using Fibroscan for ALD patients, comparing the results of them to those of virus patients and NAFLD patients.

UR - http://www.scopus.com/inward/record.url?scp=84979860385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979860385&partnerID=8YFLogxK

M3 - Article

C2 - 26946784

AN - SCOPUS:84979860385

VL - 50

SP - 235

EP - 247

JO - Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence

JF - Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence

SN - 1341-8963

IS - 5

ER -